Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
If You Invested $10,000 in Eli Lilly 10 Years Ago, This Is How Much You Would Have Today
10:00am, Friday, 03'rd Jun 2022 The Motley Fool
Is the stock a buy today?
New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS
09:20am, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced new 12-month data for tofersen, an investigational antisense drug for people with superoxide dismutase
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
07:20pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
04:33pm, Thursday, 02'nd Jun 2022
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?
03:31pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Beaten-Down Cathie Wood Stocks That Look Like Bargains
12:21pm, Thursday, 02'nd Jun 2022 The Motley Fool
These stocks are all down more than 70% from their 52-week highs.
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
06:39pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
01:00pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start late
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
10:32am, Wednesday, 01'st Jun 2022
Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start late
Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension
06:31pm, Tuesday, 31'st May 2022 Zacks Investment Research
The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.
Wide-Moat Stocks On Sale - The June 2022 Heat Map
07:20am, Tuesday, 31'st May 2022 Seeking Alpha
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison.
What Stocks To Invest In Now? 4 Biotech Stocks To Know
03:30pm, Monday, 30'th May 2022
Could these biotech stocks be worth watching in the stock market today?
Why Did Warren Buffett Just Sell 1 of His Best Stocks of 2022?
09:57am, Thursday, 26'th May 2022 The Motley Fool
The legendary investor just might regret selling this big-pharma stock.
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
04:07pm, Wednesday, 25'th May 2022 Zacks Investment Research
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
3 Dividend Stocks That Should Pay You for the Rest of Your Life
01:13pm, Monday, 16'th May 2022 The Motley Fool
Even the most aggressive, high-risk investment approach can benefit from passive income.
